# US 11,110,146 B2 · Methods for reducing platelet aggregation and treating cardiovascular disease and other medical disorders > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,110,146 B2 - Document ID: US11110146B2 - Status: Granted - Kind: B2 - Application number: 15/536,904 - Filed: 2015-12-18 - Published: 2019-03-28 - Granted: 2021-09-07 - Earliest claimed: 2014-12-19 - Assignees: Paradise Health, Inc. - Applicants: Paradise Health, Inc. - Inventors: Curt Hendrix; Jack Joseph Kleid - Web page: https://patentgrep.com/patent/US11110146B2 ## CPC - A61K 36/906: Zingiberaceae (Ginger family) - A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration} - A61P 9/02: Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives - A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure - A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis - A61P 9/12: Antihypertensives - A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The invention provides therapeutic compositions containing ground seed of Aframomum meleguata or an extract thereof, and methods for using such compositions to reduce platelet aggregation and treat medical disorders in a patient, such as cardiovascular disease. ## Claims ### Claim 1 A method of treating cardiovascular disease in a patient, comprising orally administering to a patient in need thereof an effective amount of a therapeutic composition comprising ground seed of Aframomum melegueta or an extract thereof, to treat the cardiovascular disease, wherein there is a reduction in the incidence of platelet aggregation caused by arachidonic acid, there is a reduction in the incidence of platelet aggregation caused by adenosine diphosphate, and there is a reduction in the incidence of platelet aggregation caused by collagen. ### Claim 2 (depends on 1) The method of claim 1, wherein the ground seed of Aframomum melegueta or an extract thereof is the only active ingredient for treating cardiovascular disease in the therapeutic composition. ### Claim 3 (depends on 1) The method of claim 1, wherein the therapeutic composition consists of (i) ground seed of Aframomum melegueta, an extract thereof, or both, and (b) optionally a pharmaceutically acceptable carrier. ### Claim 4 A method of reducing the risk of cardiovascular disease attributed to platelet aggregation in a patient, comprising orally administering to a patient in need thereof an effective amount of a therapeutic composition comprising ground seed of Aframomum melegueta or an extract thereof, to reduce the risk of cardiovascular disease attributed to platelet aggregation, wherein the cardiovascular disease attributed to platelet aggregation is acute coronary syndrome, myocardial infarction, stroke, peripheral arterial disease, transient ischemic attack, or angina, in each instance attributed to platelet aggregation, and there is a reduction in the incidence of platelet aggregation caused by arachidonic acid, there is a reduction in the incidence of platelet aggregation caused by adenosine diphosphate, and there is a reduction in the incidence of platelet aggregation caused by collagen. ### Claim 5 (depends on 4) The method of claim 4, wherein the ground seed of Aframomum melegueta or an extract thereof is the only active ingredient for reducing the risk of cardiovascular disease in the therapeutic composition. ### Claim 6 (depends on 4) The method of claim 4, wherein the therapeutic composition consists of (i) ground seed of Aframomum melegueta, an extract thereof, or both, and (b) optionally a pharmaceutically acceptable carrier. ### Claim 7 (depends on 4) The method of claim 4, wherein the risk of cardiovascular disease attributed to platelet aggregation is reduced for a duration of at least 1 week, 1 month, 3 months, or 6 months. ### Claim 8 (depends on 4) The method of claim 4, wherein the method achieves a reduction in the incidence of cardiovascular disease attributed to platelet aggregation by at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% in a population of patients that receive the therapeutic composition relative to a medically analogous population of patients that do not receive the therapeutic composition. ### Claim 9 (depends on 1) The method of claim 1, wherein the cardiovascular disease is acute coronary syndrome, myocardial infarction, stroke, peripheral arterial disease, transient ischemic attack, angina, or atherosclerosis. ### Claim 10 (depends on 1) The method of claim 1, wherein the therapeutic composition is administered orally at a daily dosage in the range of from about 0.1 g to about 3 g per day. ### Claim 11 (depends on 1) The method of claim 1, wherein the therapeutic composition is administered orally at a daily dosage in the range of from about 2 g to about 3 g per day. ### Claim 12 (depends on 3) The method of claim 3, wherein the therapeutic composition is administered orally at a daily dosage in the range of from about 0.1 g to about 3 g per day. ### Claim 13 (depends on 1) The method of claim 1, wherein the administering produces less gastric bleeding than aspirin administered orally at a dosage sufficient to achieve the reduction of platelet aggregation achieved using said therapeutic composition. ### Claim 14 (depends on 1) The method of claim 1, wherein the cardiovascular disease is acute coronary syndrome or myocardial infarction. ### Claim 15 (depends on 1) The method of claim 1, wherein the cardiovascular disease is stroke. ### Claim 16 (depends on 1) The method of claim 1, wherein the cardiovascular disease is peripheral arterial disease, transient ischemic attack, or angina. ### Claim 17 (depends on 3) The method of claim 3, wherein the cardiovascular disease is acute coronary syndrome or myocardial infarction. ### Claim 18 (depends on 3) The method of claim 3, wherein the cardiovascular disease is stroke. ### Claim 19 (depends on 3) The method of claim 3, wherein the cardiovascular disease is peripheral arterial disease, transient ischemic attack, or angina. ### Claim 20 (depends on 4) The method of claim 4, wherein the cardiovascular disease attributed to platelet aggregation is acute coronary syndrome or myocardial infarction, in each instance attributed to platelet aggregation. ### Claim 21 (depends on 4) The method of claim 4, wherein the cardiovascular disease attributed to platelet aggregation is stroke attributed to platelet aggregation. ### Claim 22 (depends on 4) The method of claim 4, wherein the cardiovascular disease attributed to platelet aggregation is peripheral arterial disease, transient ischemic attack, or angina, in each instance attributed to platelet aggregation.